Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Neoplasms 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 29Carboplatin 25Topotecan 12Gemcitabine 11Cyclophosphamide 11Cisplatin 11Taxes 10Filgrastim 9sargramostim 8pembrolizumab 8Docetaxel 8Bevacizumab 8Peripheral Blood Stem Cell Transplantation 6liposomal doxorubicin 5Flow Cytometry 5Interleukin-12 Subunit p35 4Drug Therapy 4fludarabine phosphate 3fludarabine 3Sirolimus 3Nivolumab 3Melphalan 3Immunohistochemistry 3Immunoenzyme Techniques 3Granulocyte-Macrophage Colony-Stimulating Factor 3Fulvestrant 3Etoposide 3Chemotherapy, Adjuvant 3Capecitabine 31-dodecylpyridoxal 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Ovarian Epithelial × quisinostat × Clear all
NCT02728492 2016-05-03

Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

NewVac LLC

Phase 1 Completed
51 enrolled
GynecologicThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡